Professor John M. Goldman CML Pioneer and Journal Founder 1938-2013
EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice: This article has been corrected since Online Publication and a corrigendum has also been published
Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors
Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma
PBSC collection from family donors in Japan: a prospective survey
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy
Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study
Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells
Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
Risk factors and organ involvement of chronic GVHD in Japan
Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials
Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning
Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT
Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant
Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation
Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT
Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT
EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL: This article has been corrected since Online Publication and a corrigendum has also been published
Distress, problems and supportive care needs of patients treated with auto- or allo-SCT
Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life
Short-term sonic-hedgehog gene therapy to mitigate myelosuppression in highly irradiated monkeys: hype or reality?
Single centre experience of haematopoietic SCT for patients with immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
Unreported use of an herbal supplement resulting in decreased clearance of intravenous busulfan in a patient undergoing auto-SCT
Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions
First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL